Состояние репродуктивной системы женщин с системной красной волчанкой (СКВ)
Диссертация
В литературе широко обсуждается роль половых гормонов в развитии заболевания. Особенностью метаболизма половых гормонов при СКВ является его гипе-рэстрогенная направленность (R.G.Lahita 2000; B.D.Greenstein 2001). Высокая заболеваемость женщин репродуктивного возраста, связь дебюта и обострений заболевания с периодами гормональной перестройки: становлением менструальной функции, беременностями… Читать ещё >
Содержание
- Основные условные обозначения и сокращения
- Глава 1. Обзор литературы
- 1. 1. Роль половых гормонов в патогенезе СКВ
- 1. 2. Нейрогуморальная регуляция репродуктивной системы
- 1. 3. Особенности репродуктивной системы женщин с СКВ
- 1. 4. Влияние терапии ЦФ на овариальную функцию больных СКВ
- Глава 2. Материал н методы исследования
- 2. 1. Клиническая характеристика обследованных больных
- 2. 2. Методы исследования
- Глава 3. Результаты собственных исследований
- 3. 1. Оценка репродуктивной системы женщин с СКВ
- 3. 1. 1. Характеристика менструальной функции
- 3. 1. 2. Детородная функция
- 3. 1. 3. Препараты женских половых гормонов и СКВ
- 3. 1. 4. Гинекологические заболевания
- 3. 2. Характеристика гормонального статуса больных СКВ
- 3. 3. Терапия ГК и овариальная функция больных СКВ
- 3. 4. Влияние терапии ЦФ на овариальную функцию больных СКВ. ретроспективное исследование)
- 3. 5. Овариальная функция больных СКВ в динамике на фоне. терапии ЦФ (проспективное исследование)
- 3. 1. Оценка репродуктивной системы женщин с СКВ
- Глава 4. Обсуждение
- Выводы
Список литературы
- Адамян JI.B. Генитальный эндометриоз. В книге: Кулаков А. И., Селезнева Н. Д., Краснопольский В. И. Оперативная гинекология, Ниж. Новгород, «НГМА». 1998: 249.
- Алекберова З.С., Карабаева А. С., Кошелева Н. М. СКВ: начало у лиц в возрасте старше 45 лет. Клин. Геронтология. 2002- 8 (3): 16−21.
- Алекберова З.С., Кошелева Н. М., Белецкая С. Г. Мониторинг активности СКВ при беременности. Тер. Архив. 1994- 10: 46−51.
- Алекберова З.С., Фоломеев М. Ю. Половой диморфизм при ревматических заболеваниях. Ревматология. 1985- 2: 58−61.
- Барроу Д. Н. Щитовидная железа и репродукция. В книге: Йен С.С.К., Джаффе Р. Б. Репродуктивная эндокринология. Руководство в 2-х томах- Пер. с англ. М. «Медицина». 1998- Т.1: 587−611.
- Вихляева Е.М. Руководство по эндокринной гинекологии. М., «Мед. Информ. Агентство». 2002: 139−140, 150−175.
- Кошелева Н.М. Системная красная волчанка и беременность: мониторинг активности заболевания и антифосфолипидного синдрома. Дисс. .канд. мед. наук. М., 1994.
- Кулаков В.И., Сметник В. П. Руководство по климактерию. М., «Мед. Информ. Агентство». 2001: 13−18.
- Манухин И.Б., Тумилович Л. Г., Геворкян М. А. Клинические лекции по гинекологической эндокринологии. М., «Мед. Информ. Агентство». 2001: 6−25, 40, 102, 121−122.
- Ю.Насонов Е. Л., Клюквина Н. Г., Масенко В. П., Алекберова З. С. Пролактин при ревматических заболеваниях. Клиническая ревматология. 1997- 2: 23−38.
- П.Насонов Е. Л. Противовоспалительная терапия ревматических болезней. М., «М-СИТИ». 1996:97−103.
- Насонов Е.Л., Чичасова Н. В., Ковалев В.10. Глюкокортикоиды в ревматологии. Москва. 1998: 36−38.
- Насонова В.А. Системная красная волчанка. М., «Медицина». 1972.
- Насонова В.А., Астапенко М. Г. Клиническая ревматология. Руководство.
- М. «Медицина». 1989: 14−174. 15.0садчая О.В., Лысенко О. В. Нарушения менструального цикла. С.-Петербург. «ДИЛЯ». 2003: 13−25, 27−35.
- Прилепская В.Н., Рудакова Е. Б., Кононов А. В. Эктопии и эрозии шейки матки. М., «Мед. Прес. Информ.». 2002: 19.
- Прокаева Т.Б. Ревматоидный артрит у мужчин (клиническая характеристика и особенности гормонального статуса). Дисс. .канд. мед. наук. М., 1991.
- Реброва 0.10. Статистический анализ медицинских данных. М., «МЕДИА СФЕРА». 2002.
- Савельева Г. М. Справочник по акушерству и гинекологии. М., «Медицина». 1996: 29−32, 232−234, 249.
- Савельева Г. М., Лобова Т. А., Олимпнева С. П. и соавт. Анализ особенностей репродуктивного поведения женщин путь к разработке программы снижения числа абортов. Вестник российской ассоциации акуш.-гинекологов. 1998- 1.
- Селезнева Н.Д. Доброкачественные опухоли и опухолевидные образования внутренних половых органов. В книге: Кулаков А. И., Селезнева Н. Д., Краснопольский В. И. Оперативная гинекология, Ниж. Новгород, «НГМА». 1998: 167.
- Сметник В.П., Тумилович Л. Г. Неоперативная гинекология. М., «Мед. Информ. Агентство». 2001: 40−43, 54−81, 174−175, 227−238.
- Служба охраны здоровья матери и ребенка в 2002 году. Минздрав Российской федерации. Москва, 2003.
- Таранов А.Г. Диагностические тест-системы (радиоиммуиный и иммуноферментный методы диагностики). М., «Издатель Мокеев». 2002.
- Тихомиров А. Л, Лубнин Д. М. Преимущество Бусерелипа в терапии миомы матки. В сборнике статей: опыт применения бусерелина в гинекологической практике. М., «ФАРМ-СИНТЕЗ». 2003: 3−6.
- Фоломеев М.Ю. Системная красная волчанка у мужчин. Дисс. .канд. мед. наук. М., 1974.
- Шардина JI.A. Гонадотропные и половые гормоны, менструальная и генеративная функции у женщин с системной красной волчанкой. Дисс. .канд. мед. наук. Ярославль, 1989.
- Шахраманова e.ji. Ревматоидный артрит у женщин репродуктивного возраста (клиника и гормональный статус). Афтореф. дне. канд. мед. наук. М., 2000.
- Adler R.A. The anterior рituitary-grafted rat: a valid model of chronic hyperprolactinemia. Endocrin. Rev. 1986- 7: 302−313.
- Aguirre M.A., Jimena P., de Andres M. et al. Gynaecological abnormalities in women with systemic lupus erythematosus: a prospective controlled study. Br. J. Rheumatol. 1997- 36: 4 abstract.
- Ahmed Ebbiary N.A., Lenton E.A., Salt C. The significance of elevated basal follicle stimulating hormone in regularly menstruating infertile women. Hum. Reprod. 1994- 9: 245−252.
- Alarcon-Serovia D, Alarcon-Riquelrne M.E. Etiopathogenesis of systemic lupus erythematosus: a tale of three troikas. In Lahita R.G. (ed). Systemic lupus erythematosus, ed 3. San Diego, Academic Press. 1999: 55−65.
- Alvarez-Nemegyei J., Cobarrubias-Cobos A., Escalante-Triay F. et al. Bromocriptine in in systemic lupus erythematosus: a double-blind, randomized, placebo-controlled study. Lupus. 1998- 7: 414−419.
- Arnalich F., Benito U.S., Gonzales G.P. et al. Inadequate production of the progesterone in women with systemic lupus erythematosus. Br. J. Rheumatol. 1992- 31:247−251.
- Asherson R.A., Harris E.N., Hughes G.R. Complications of oral contraceptives and antiphospholipid antibodies. Arthritis Rheum. 1988- 31: 575−576.
- Ataya K.M., Valeriote F.A., Ramahi-Ataya A. Effects of cyclophosphamide on immature rat ovary. Cancer Res. 1989- 49: 1660−1664.
- Austin H.A., Klippel J.H., Balow J.E., et al. Therapy of lupus nephritis: controlled trial of prednizolon and cytotoxic drugs. N. Engl. J. Med. 1986- 314: 614- 619.
- AxelrodL. Glucocorticoid therapy. Medicine. 1976- 55: 39−65.
- Bakchine H., Brauner R., Thibaud E. et al. Chemotherapy and ovarian function. Retrospective analysis in 17 girls treated for malignant tumor or hematologic disease. Arch. Fr. Pediatr. 1986−43:611−616.
- Baker J.R. Jr., Miller F.W., Steinberg A.D. et al. Thyroid stimulating and thyrotrophin binding-inhibitory immunoglobulin activity in patients with systemic lupus erythematosus having thyroid function abnormalities. Thyroid. 1991- 1: 229−234.
- Barrett C., Neylon N., Snaith M. Estrogen-induced systemic lupus erythematosus. Br, J. Rheumatol. 1986- 25: 300−301.
- Bateman H., Yazici Y., Leff L. et al. Increased cervical dysplasia in intravenosus cyclopnosphamide-treated patients with SLE: preliminary study. Lupus. 2000- 9: 542 544.
- Batticane N., Morale M.C., Gallo F. et al. Luteinizing hormone-releasing hormone signaling at lymphocyte involves stimulating of interleukin-2 receptor expression. Endocrinology. 1991- 129: 277−286.
- Beeson P.B. Age and sex associations of 40 autoimmune diseases. Am. J. Med. 1994- 96: 457−462.
- Ben-Chetrit A., Ben-Chetrit E. Systemic lupus erythematosus induced by ovulation induction treatment. Arthritis Rheum. 1994- 37 (11): 1614−1617.
- Benito U.S., Huarte L.E., Gijon B.J. et al. Hormonal changes in fertile women with quiescent systemic lupus erythematosus. An. Med. Interna. 1995- 12 (5): 221−224.
- Berthier S., Mougin C., Vercherin P. et al. Human papillomavirus infection and cervical cancer risk in women with systemic lupus erythematosus. Rev. Med. Interne. 1999- 20: 128−132.
- Blanco Favela F., Quintal-Alvarez G, Leanos-Miranda A. Association between prolactin and disease activity in systemic lupus erythematosus. Influence of statistical power. J. Rheumatol. 1999- 26: 55−59.
- Blumenfeld Z., Avivi I., Ritter M. et al. Preservation of fertility and ovarian function and minimizing chemotherapy-induced gonadotoxicity in young women. J. Soc. Gynecol. Invest. 1999- 6: 229−239.
- Blumenfeld Z., Shapiro D., Shteinberg M. Preservation of fertility and ovarian function and minimizing gonadotoxicity in young women with systemic lupus erythematosus treated by chemotherapy. Lupus. 2000- 9: 401−405.
- Bombardier C., Gladman D.D., Vrowitz et al. Derivation of the SLEDAI. A disease activity index for lupus patients. Arthritis Rheum. 1992- 35: 630−640.
- Boumpas D.T., Austin H.A., Vaughn E.M. et al. Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy. Ann. Intern. Med. 1993- 119: 366−369.
- Brodsky R.A., Petri M., Smith B.D. et al. Immunoablative high-dose cyclophosphamide without stem cell rescue for refractory, severe autoimmune disease. Ann. Intern. Med. 1998- 129: 1031−1035.
- Bucala R., Lahita R.G., Fishman J. et al. Anti-oestrogen antibodies in users of contraceptives and patiens with systemic lupus erythematosus. Clin. Exp. Immunol. 1987- 67 (1): 167−175.
- Buskila D., Lorber M., Neumann L. et al. No correlation between prolactin levels and clinical activity in patients with systemic lupus erythematosus. J. Rheumatol. 1996- 23: 629−632.
- Byron M.A., Mowat A.G. Thyroid disorders in systemic lupus erythematosus (letter). Ann. Rheum. Dis. 1987- 46: 174−175.
- Candy C.J., Wood M.J., Whittingham D.G. Follicular development in cryopreserved marmoset ovarian tissue after transplantation. Hum. Reprod. 1995- 10 (9): 2334−2338.
- Casoli P., Tumaki В., La Sala G. Fatal exacerbation of SLE after induction of ovulation. J. Rheumatol. 1997- 24: 1639−1640.
- Chapman R.M., Sutcliffe S.B. Protection of ovarian function by in women receiving chemotherapy for Hodgkins disease. Blood. 1981- 58 (4): 849−851.
- Charles J., Grossman C., Gary A. et al. Peptide Hormones. Progress in Clin. Biochem. and Med. 1986- 4: 7−8.
- Cheung C.Y. Prolactin supress luteinizing hormone secretion and pituitary responsiveness to luteinizing hormone-releasing hormone by a direct action at the anterior pituitary. Endocrinology. 1983- 112:632−638.
- Chrousos G.P., Torpy D.J., Gold P.W. Interactions between the hypothalamic-pituitary-adrenal axis and the female reproductive system: clinical implications. Ann. Intern. Med. 1998- 129: 229−240.
- Clevenger C.V., Russel D.H., Appasamy P.M. et al. Regulation of interleukin-2 driven T-lymphocytes prolipheration by prolactin. Proc. Natl. Acad. Sci. USA. 1990- 87: 6460−6464.
- Cox S.L., Shaw J., Jenkin G. Transplantation of cryopreserved fetai ovarian tissue to adult recipient in mice. J. Reprod. Fertil. 1996- 107: 315−322.
- Culoto M., Sulli A., Seriolo B. Estrogens, the immune response and autoimmunity. Ciin. Exp. Rheumatol. 1995- 13: 217−226.
- D’Cruz D., Cuadrado M.J., Mujic F. et al. Immunosupressive therapy in lupus nephritis. Clin. Exp. Rheumatol. 1997- 15: 275−282.
- Davis J.C., Klippel J.H. Antimalarias and immunosupressive drugs. In Lahita R.G. (ed). Systemic lupus erythematosus, ed 3. San Diego, Academic Press. 1999: 967−984.
- Dawood M.Y., Ramos J., Khan-Dawood F.S. Leuprolide acetate versus danasol for treatment of pelvic endometriosis: changes in vertebral bone mass and serum estradiol and calcitonin. Fertil. Steril. 1995- 63 (6): 1177−1183.
- Dlugi A.M., Miller J.D., Knittle J. Lupron depot (leuprolide acetate for depot suspension) in the treatment of endometriosis: a randomized, placebo-controlled, double-blind study. Fertil. Steril. 1990- 54: 419−426.
- Duffy D.A., Denners M.L., Molin M.R. Systemic lupus erythematosus and breast gigantism. J. Rheumatol. 1995- 22: 1214−1215.
- Ehring G.R., Kerschbaaum H.H., Eder C., et al. A non-genomic mechanism for progesterone-mediated immunosuppression: Ingibition of K+ chanels, Ca+ signaling, and gene expression in T- lymphocytes. J. Exp. Med. 1998- 188: 1593−1595 .
- Eustace D.L.S. Systemic lupus erythematosus and uterine cervical dysplasia. (Editoral). Lupus. 1994- 3: 59−61.
- Feld S., Landau Z., Gefel D. et al. Pernicious anemia. Hashimoto’s thyroiditis and Sjogren’s in woman with SLE and autoimmune hemolytic anemia (letter). J. Rheumatol. 1989- 16: 258−259.
- Fenichel P., Sosset C., Barbarino-Monnier P. et al. Prevalence, specificity and significance of ovarian antibodies during spontaneous premature ovarian failure. J. Hum. Reproduction. 1997- 12 (12): 2623−2628.
- Fogelman I. Gonadotropin-releasing hormone agonists and the sceleton. Fertil. Steril. 1992- 57:715−724.
- Formiga F., Moga I., Рас M. Mild presentation of systemic lupus erythematosus in elderly patients assessed by SLEDAI. Lupus. 1999- 8: 462−465.
- Funauchi M., Ikoma S., Enomoto H. Decreased Thl-like and increased Th2-like cells in systemic lupus erythematosus. Scand. J. Rheumatol. 1998- 27: 219−224.
- Furakava F., Tachibana Т., Imamura S. Oral contraceptive-induced systemic lupus erythematosus in a Japanese woman. J. Dermatol. 1991- 186: 56−58.
- Gallant C., Kenny P. Oral glucocorticoids and their complication. A review. J. Am. Acad. Dermatol. 1986- 14: 161−177.
- Garovich M., Agudelo C., Pisko E. Oral contraceptives and systemic lupus erythematosus. Arthritis Rheum. 1980- 23: 1396−1398.
- Gatenby P.A. Systemic lupus erythematosus and pregnancy. Aust. N.Z.J. Med. 1989- 19: 261−278.
- Gonzalez-Crespo M.R., Gomez-Reino J.J., Merino R. et al: Menstrual disorders in gerls with systemic lupus erythematosus. Br. J. Rheumatol. 1995- 34: 737−743.
- Gook D.A., Osborn S.M., Bourne H. et al. Fertilization of human oocytes following cryopreservation: normal karyotypes and absence of stray chromosomes. Hum. Reprod. 1994- 9 (4): 684−691.
- Grasso G., Massai L., De Leo V. et al. The effect of LHRH and TRH on human interferon-T production in vivo and in vitro. Life Sci. 1998- 62: 2005−2014.
- Greenstein B.D. Lupus: Why women? Journal of women’s health. 2001- 3 (10): 233 239.
- Grossman C. Possible underlying mechanisms of sexual dimorphism in the immune response, fact and hypothesis. J. Steroid. Biochem. 1989- 34: 241−251.
- Grossman С., Gary A., Roselle M.D. Effect of progesterone on immune response. Progress in Clin. Biochem. and Med. 1986- 4: 16−17.
- Grossman C., Roselle G.A. Control of immune response by endocrine factors and the clinical significance of such regulation. Progress in Clin. Biochem. and Med. 1986- 4: 9−56.
- Grossman C.J. Interaction between the gonadal steroids and the immune system. Science. 1985−227:257−261.
- Gutierrez M.A., Cabrera G.E., Cuellar M.L. et al. Prolactin induced autoantibody formation by PBL of normal individuals and SLE patients. Arthritis Rheum. 1993- 36: (suppi) SI97.
- Hakuno N., Koji Т., Yano T. et al. Fas/APO-l/CD95 system as a mediator of granulosa cell apoptosis in ovarian follicle atresia. Endocrinology. 1996- 137: 1938−1948.
- Herrmann M., Winkler Т., Gaipl U. Etiopathogenesis of systemic lupus erythematosus. Int. Arch. Allergy Immunol. 2000- 123: 28−35.
- Hovatta O. Cryopreservation of human ovarian tissue using dimethylsulphoxide and propanediol-sucrose as ciyoprotectants. Hum. Reprod. 1996- 11 (6): 1268−1272.
- Huang C-M., Chou C-T. Hyperprolactinemia in systemic lupus erythematosus. Clin. Med. J. 1997- 59:37−41.
- Hunter J.L. Cryopreservation of human pophase I oocytes collected from unstimulated follicles. Fertil. Steril. 1994- 61 (6): 1077−1082.
- Huong D.L., Weschler В., Piette J.C. Risk of ovulatio- induction therapy in systemic lupus erythematosus. Br. J.Rheumatol. 1996- 65 (11): 1184−1186.
- Huong Du Le Thi, Amoura Z, Duhaut P. Risk of ovarian failure and fertility after intravenous cyclophosphamide. A study in 84 patients. J. Rheumatol. 2002- 29 (12): 2571−2576.
- Ishizuka В., Kudo Y., Amemiya A. et al. Anti-nuclear antibodies in patients with premature ovarian failure. J. Hum. Reproduction. 1999- 14 (1): 70−75.
- Jacobson J.D., Ansari M.A., Kinealy M. et al. Gender specific exacerbation of murine lupus by gonadotropine-releasing hormone: potential role of Ga9/ll. Endocrinology. 1999- 140: 3429−3437.
- Jacobson J.D., Crofford L.J., Sun L. et al. Cyclical expression of GnRH and GnRH receptor mRNA in lymphoid organs. Neuroendocrinology. 1998- 67: 117−125.
- Jara L.J., Gomez-Sanchez C., Silveria L.H. et al. Hyperprolactinemia in systemic lupus erythematosus: Association with disease activity. Am. J. Med. Sci. 1992- 303: 222−226.
- Jara-Quezada L., Graef A., Lavalle C. Prolactin and gonadal hormones during pregnancy in systemic lupus erythematosus. J. Rheumatol. 1991- 18: 349−353.
- Jewelewiez R., Schwartz M. Premature ovarian failure. Bull N.Y. Acad. Med. 1986- 62: 219−236.
- Jimena P., Aguirre M.A., Lopez-Curbelo A. et al. Prolactin levels in patients with systemic lupus erythematosus: a case controlled study. Lupus. 1998- 7: 383−386.
- Johansen J.S. The effects of a gonadotropin-releasing hormone agonist analog (nafarelin) on bone metabolism. J. Clin. Endocrinol. Metab. 1988- 67: 701−706.
- Julkunen H.A. Oral contraceptives and systemic lupus erythematosus: side effects and influence on the activity of SLE. Scand. J. Rheumatol. 1991- 20: 427−433.
- Julkunen H.A., Kaaja R., Friman C. Contraceptive practic in women with systemic lupus erythematosus. Br. J. Rheumatol. 1993- 32: 227−230.
- Jungers P., Dougados M., Pelissier C. Influens of oral contraceptive therapy on the activity of systemic lupus erythematosus. Arthritis Rheum. 1982- 25: 618−623.
- Kanda N., Tsuchida Т., Tamaki K. Testosterone suppresses anti-DNA antibody production in peripheral blood mononuclear cells from patients with systemic lupus erythematosus. Arthritis Rheum. 1997- 40: 1703−1711.
- Katsifis G., Tzioufas A.G., Ioannidis J.P.A. Parameters modulating the risk of sustained amenorrea from pulsed intravenous cyclophosphamide in premenopausalwomen with systemic lupus erythematosus, abstract., Clin. Exp. Rheumatol. 2002- 20 (2): 267.
- Kausman D., Isenberg D.A. Thyroid autoimmunity in systemic lupus erythematosus: the clinical significance of a fluctuating course. Br. J. Rheumatol. 1995- 34: 361−364.
- Koutras D.A. Disturbances of menstruation in thyroid disease. Ann. NY. Acad. Sci. 1997- 816: 280−284.
- Lado-Abeal J., Rodrigues-Arnao J., Newell-Price J.D. Menstrual abnormalities in women with Cushing’s disease are correlated with hypercortisolemia rather than raised circulating androgens levels. J. Clin. Endocrinol. Metab. 1998- 83: 3083−3088.
- Lahat V. et al. Differential effects of proiaciin upon activation and differentiation of human В lymphoctes. J. Neuroimmunol. 1993- 47: 35−40
- Lahita R.G. Gender and age in lupus. In Lahita RG (ed). Systemic lupus erythematosus, ed 3. San Diego, Academic Press. 1999: 129−144.
- Lahita R.G. Sex hormones and systemic lupus erythematosus. Rheum. Dis. Clin. North. Am. 2000- 26 (4): 951−968.
- Lahita R.G. Sex hormones as immunomodulators of disease. Ann. NY. Acad. Sci. 1993−685:278−287.
- Lahita R.G. Sex steroids and SLE: Metabolism of androgens to estrogens editorial. Lupus. 1992- 1: 125−127.
- Lahita R.G. The importance of estrogens in systemic lupus erythematosus. Clin. Immunol. Immunopathol. 1992- 63: 17−18.
- Lahita R.G. The influence of sex hormones on the diseases systemic lupus erythematosus. Springer Semin. Immunopathol. 1986- 9: 305−314.
- Lahita R.G., Bradlow H.L., Ginzler E. Low plasma androgens in women with systemic lupus erythematosus. Arthritis Rheum. 1987- 30: 241−248.
- Lahita R.G., Bradlow H.L., Kunkel H.G. et al. Increased 16-hydroxylation of estradiol in systemic lupus erythematosus. J. Clin. Endocrinol. Metab. 1981- 53: 174−178.
- Lahita R.G., Merrill J.T. Cystic ovaries and Stein-Leventhal syndrome in patients with systemic lupus erythematosus. Arthritis Rheum. 1995- 38: (suppl) S392.
- Leanos A., Pascoe D., Fraga A. et al. Anti-prolactin autoantibodies in systemic lupus erythematosus patients with associated hyperprolactinemia. Lupus. 1998- 7: 398−403.
- Lenton E.A., Sexton L., Lee S. Progressive changes in LH and FSH and LH:
- FSH ratio in women throughout reproductive life. Maturitas. 1988- 10: 35−43.
- Lim G.S., Petri M., Goldman D. Menstruation and systemic lupus erythematosus (SLE): a case-control study, abstract. Arthritis Rheum. 1993- 36: (suppl 5) R23.
- Lima F.R., Guerra D., Sella E.M.C. et al. Systemic lupus erythematosus (SLE) and cervical intraepithelial neoplasia. Arthritis Rheum. 1998- 41: (suppl) S66.
- Manzi S., Meilahn E., Rairi J. et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham study. Am. J. Epidemiol. 1997- 145: 408−415.
- Masi A.T., Feigenbaum S.L., Chatterton R.T. et al. Integrated hormonal-immunological-vascuiar (H-I-V triad) systems in the rheumatic diseases. Clin. Exp. Rheumatol. 1995- 13: 203−216.
- McDermott E.M., Powell R.J. Incidence of ovarian failure in systemic lupus erythematosus after treatment with pulse cyclophosphamide. Ann. Rheum. Dis. 1996- 55: 224- 229.
- McMurray R.W., Weidensaul D., Allen S.H. et al. Efficacy of bromocriptine in an open label therapeutic trial for systemic lupus erythematosus. J. Rheumatol. 1995- 22: 2084−2091.
- Medeiros M.M., Silveria V.A., Menezes A.P. et al. Risk factors for ovarian failure in patients with systemic lupus erythematosus. Braz. J. Med. Biol. Res. 2001- 34 (12): 1561−1568, 133A.
- Meier C.R., Sturkenboom M.C., Cohen A.S. Postmenopausal estrogen replacement therapy and the risk of developing systemic lupus erythematosus or discoid lupus. J. Rheumatol. 1998- 25: 1515−1519.
- Miller M.H., Urowitz M.B., Gladman D.D. et al. Systemic lupus erythematosus in males. Medicine. 1983- 62: 327−334.
- Miranda J.M., Prieto R.E., Paniagua R. et al. Clinical significance of serum and urine prolactin levels in lupus glomerulonephritis. Lupus. 1998- 7: 387−391.
- Mok C.C., Lau C.S., Ho C.T.K. Do flares of systemic lupus erythematosus decline after menopause? Scand J Rheumatol. 1999- 28: 357−362.
- Мок C.C., Lau C.S., Wong R.W. Risk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophosphamide therapy. Arthritis Rheum. 1998- 41: 831−837.
- Мок С.С., Lau C.S., Wong R.W. Use of exogenous estrogens in systemic lupus erythematosus. Semin. Arthritis Rheum. 2001- 30 (6): 426−435.
- Мок C.C., Wong R.W., Lau C.S. Ovarian failure and flares of systemic lupus erythematosus. Arthritis Rheum. 1999- 42: 1274−1280.
- Molitch M.E. Pathologic nyperprolactinemia. Endocrinol. Metab. Clin. N. Am. 1992- 21: 877−901.
- Moncayo-Naveda H., Moncayo R., Benz R. Organ-specific antibodies against ovary in patients with systemic lupus erythematosus. Am. J. Obstet. 1989- 160: 1227−1229.
- Montz F.J., Wolff A.J., Gambone J.C.G. Gonadal protection and fecundity rates in cyclophosphamide treated rats. Cancer Res. 1985- 45: 3651−3656.
- Morris V.H., Hakim A., Iscnberg D.A. Rewiew of gynaecological abnormalities in patients with systemic lupus erythematosus. Arthritis Rheum. 1998- 41: (suppl) S106.
- Munoz J.A., Gil A., Lopez-Dupla J.M. et al. Sex hormones in chronic systemic lupus erythematosus. Ann. Med. Interne. 1994- 145 (7): 459−463.
- Munster K., Schmidt L., Helm P. Length and variation in the menstrual cycle a cross-sectional study from a Danish country. Br. J. Obstet. Gynaecol. 1992- 99 (5): 422−429.
- Nakagawa H., Min K.R., Nanjo K. et al. Anti-inflammatory action of progesterone on carrageenin-induced inflammation in rats. J. Pharmacol. 1979- 25 (4): 509−514.
- Neidhart M. Elevated serum prolactin or elevated prolactin/cortisol ratio are associated with autoimmune progress in systemic lupus erythematosus and other connective tissue diseases. J. Rheumatol. 1996- 23: 629−632.
- Nelson A.M., Conn O.L. Glucocorticoids in rheumatic disease. Mayo Clin. Proc. 1980- 55: 758−769.155.01sen N.J., Viselli S.M., Pan J. Et al. Androgens accelerate thymocyte apoptosis. Endocrinology. 1998- 139: 748−752.
- Oviasu E., Hicks J., Cameron J.S. The outcome of pregnancy in women with lupus nephritis. Lupus. 1991- 1: 19−25.
- Paavonen Т., Aronen H., Pyrhonen S. The effects of anti-estrogen therapy on lymphocyte functions in breast cancer patients. APMIS. 1991- 99: 163−170.
- Pasoto S.G., Abrao M.S., Viana V.S.T. et al. Is endometriosis associated with systemic lupus erythematosus? Arthritis Rheum. 2001- 44 (9): (suppl.) S290.
- Pasoto S.G., Mendonca B.B., Bonfa E. Menstrual disturbances in patients with systemic lupus erythematosus without alkylating therapy: clinical, hormonal and therapeutic associations. Lupus. 2002- 11: 175−180.
- Pasoto S.G., Viana V.S., Mendonca B.B. Anti-corpus luteum antibody: a novel serological marker for ovarian dysfunction in systemic lupus erythematosus? J. Rheumatol. 1999- 26: 1087−1093.
- Pauzner R., Urowitz M.B., Gladman D.D. et al. Prolactin in systemic lupus erythematosus. J. Rheumatol. 1994- 21: 2064−2067.
- Pekopen F., Siegberg R., Makinen T. Immunological disturbances in patients with premature ovarian failure. Clin. Endocrinol. 1986- 25: 1−6.
- Petri M., Howard D., Repke J. Frequency of lupus flare in pregnancy: the Hopkins Lupus Pregnancy Center experience. Arthritis Rheum. 1999- 42: 1274−1280.
- Petri M., Karlson E.W., Cooper D.S. et al. Autoantibody tests in autoimmune thyroid disease. J. Rheumatol. 1991- 18: 1529−1531.
- Petri M., Robinson C. Oral contraceptives and systemic lupus erythematosus. Arthritis Rheum. 1997- 40: 797−803.
- Plotz C.M., Knowlton A.I., Ragan C. The natural history of Cushing’s syndrome. Am. J. Med. 1952- 13:597−614.
- Rose E., Pillsbury D.M. Lupus erythematosus and ovarian function: observations on a possible relationship, with report of six cases. Ann. Intern. Med. .1944- 21: 1022−1034.
- Rovensky J., Jurankova E., Rauova L. et al. Relationship between endocrine, immune, and clinical variables in patients with systemic lupus erythematosus. J. Rheumatol. 1997−24:2330−2334.
- Sakakura N., Takebe K., Nakagawa S. Inhibition of luteinizing hormone secretion induced by synthetic LRH by long-term treatment with glucocorticoids in human subjects. J. Clin. Endocrinol. Mctab. 1975- 40: 774−779.
- Sakata S., Nakamura S., Nagai K. et al. Two cases of systemic lupus erythematosus associated with hypothyroidism. Jpn. J. Med. 1987- 26: 373−376.
- Saketos M., Sharma N., Santoro N.F. Suppression of the hypothalamic-pituitary-ovarian axis in normal women by glucocorticoids. Biol. Reprod. 1993- 49: 1270−1276.
- Sanchez M.L., Gomez-Pacheco L., Zonana-Nacach A. et al. Long term follow up of diffuse proliferative glomerulonephritis in SLE after two years of intravenous cyclophosphamide therapy abstract. Arthritis Rheum. 1997- 40: (suppl) S57.
- Sanchez-Guerrero J., Liang M.N., Karlson E.W. Past use of oral contraceptives and the risk of developing systemic lupus erythematosus. Arthritis Rheum. 1997- 40: 804 808.
- Sanchez-Guerrero J., Liang M.N., Karlson E.W. Postmenopausal estrogen therapy and the risk for developing systemic lupus erythematosus. Ann. Intern. Med. 1995- 122: 430−433.
- Schaller J. Lupus in childhood. Clin. Rheum. Dis. 1982- 8: 219−228.
- SciaIli A.R., Jestila K.J., Simon J.A. Leuprolide acetate and bone mineral density measured by quantitive radiography. Fertil. Steril. 1993- 59 (3): 674−676.
- Scully R.E., Mark E.J., McNeely B.U. Case records of the Massachusetts General Hospital. Case 46−1986. New Engl. J. Med. 1986- 315: 1336−1343.
- Silva C.A.A., Leal M.M., Leone C. Gonadal function in adolescents and young women with juvenile systemic lupus erythematosus. Lupus. 2002- 11: 419−425.
- Slater C.A., Liang M.H., McCune J.W. et al. Preserving ovarian function in patients receiving cyclophosphamide. Lupus. 1999- 8: 3−10.
- Smith S., Howell R., Scott L. Is endometriosis associated with systemic lupus erythematosus? Int. J. Fertil. 1993- 38: 343−346.
- Sortino M.A., Wise P.M. effect of age and long term ovariectomy on prolactin secretion, as assessed by the reverse homolytic plaque assay. Endocrinol. 1989- 124: 90−96.
- Spangelo B.L. et al. Stimulation of in vivo antibody production and cocanavalin-A-induced mouse spleen cell mitogenesis by prolactin. Immunopharmacol. 1987- 14: 1120.
- Steinberg A.D., Steinberg BJ. Lupus disease activity associated with menstrual cycle. J.Rheumatol. 1985- 12(4): 816−817.
- Sthoeger Z.N., Chiorazzi R.G., Lahita R.G. Regulation of the immune response by sex steroids. J. Immunol. 1988- 141: 91−98.
- Stites D.P., Bugbee S., Siiteri P.K. Differential actions of progesterone and Cortisol on lymphocyte and monocyte interaction during lymphocyte activation- Relevance to immunosuppression in pregnancy. J. Reprod. Immunol. 1983- 5: 215- 218.
- Stites D.P., Siiteri P.K. Steroids as immunosuppressants in pregnancy. Immunol. Rev. 1983- 75:117−138.
- Szekeres- Bartho J., Par G., Szereday L. et al. Progesterone and non-specific immunologic mechanisms in pregnancy. Am. J. Reprod. Immunol. 1997- 38: 176 179.
- TakuwaN., Kojima I., Ogata E. Lupus-like syndrome rare complication of thionamide treatment for Graves" disease. Endocrinol. Jpn. 1981- 28: 663−667.
- Tan E.M., Cohen A.S., Fries J.S. et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1992- 25: 1271−1277.
- Toth T.L. et al: Cryopreservation of human pophase I oocytes collected from unstimulated follicles. Fertilization and in vitro development of cryopreserved human pophase I oocytes. Fertil. Steril. 1994- 61 (5): 891−894.
- Van V.R., McGuire J.L. Estrogen, progesteron, and testosterone: Can they be used to treat autoimmune diseases? Cleve Clin. J. Med. 1994- 61: 276−284.
- Van Vollenhoven R.F. Dehydroepiandrosterone in systemic lupus erythematosus.. Rheum. Dis. Clin. North. Am. 2000- 26 (2): 349−362.
- Vegetti W., Marozzi A., Manfredini E. Premature ovarian failure. Mol. Cell Endocrinol. 2000- 161 (1−2): 53−57.
- Verthelyi D., Sex hormones as immunomodulators in health and disease. Intern. Immunopharmacology. 2001- 1: 983−993.
- Walker S.E., Jacobson J.D. Roles of prolactin and gonadotropin-releasing hormone in rheumatic diseases. Rheum. Dis. Clin. North. Am. 2000- 26: 713−736.
- Walker S.E., McMurray R.W., Besch-Williford C.L. et al. Premature death with bladder outlet obstruction and hyperprolactinemia in NZB/NZW mice treated with ethinyl estradiol and 17 beta-estradiol. Arthritis Rheum. 1992- 35: 1387−1392.
- Wallace D.J., Dubois E.L. Clinical and laboratory manifestations of SLE. In Dubois' Lupus erythematosus, ed 3. Philadelphia, PA, Lea & Febiger. 1987: 317−449.
- Wang CL, Wang F, Bosco JJ: Ovarian failure in oral cyclophosphamide treatment for systemic lupus erythematosus. Lupus. 1995- 4: 11−14.
- Wilson W.A., Charavi A.E., Koike T. et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum. 1999- 42: 1309−1311.
- Yu Hsu S., Jen-May Lai R., Finegold M. et al. Targeted overexpression of Bcl-2 in ovaries of transgenic mice leads to decreased follicle apoptosis, enhanced folliculogenesis, and increased germ cell tumorigenesis. Endocrinology. 1996- 137: 4837−4843.
- Zhang J et al: Extracorporeal development and ultrarapid freezing of human fetal ova. J. Assist. Reprod. Gent. 1995- 12 (6): 361−368.